Patient-Reported Outcomes With Roflumilast Foam 0.3% in Patients With Psoriasis of the Scalp and Body in the Phase 3 ARRECTOR Trial. J of Skin 2025, 9 (2), s525. https://doi.org/10.25251/skin.10.supp.525.